ArticleJAC-antimicrobial resistance2026
Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Patients requiring prolonged intravenous (IV) antibiotics often face extended hospital stays for daily administration, placing significant demands on healthcare resources. Oritavancin, a long-acting lipoglycopeptide licensed for gram-positive acute bacterial skin and skin structure infections, offers potential savings in bed-days and overall costs and potential value for patients with adherence challenges such as people who inject drugs (PWID). However, data regarding off-label use are limited. To evaluate the clinical effectiveness, hospital bed-day savings and cost-effectiveness of off-label oritavancin use in patients with complex gram-positive infections. Methods: This retrospective case series reviewed patients treated with off-label oritavancin from 2022 to 2024. Data collected included infection types, dosing regimes, duration of prior inpatient therapy and clinical outcomes. Clinical cure was defined as resolution of infection without recurrence within 30 days of the final dose of oritavancin. Bed-days saved and cost savings were calculated. Results: Twenty-five patients received off-label oritavancin. Conclusions: Oritavancin demonstrates significant clinical effectiveness and net cost savings in the off-label treatment of complex gram-positive infections. However, limited follow-up restricts assessment of long-term outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.